HMN 2026: What is the Molecular ‘switch’ that fuels cancer progression

Researchers from the University of Cape Town’s (UCT) Scientific Computing Research Unit (SCRU) have uncovered a critical molecular “switch” that drives the formation of cancer-associated antigens. The study, published in Nature Communications, details how the spatial relocation of enzymes within a cell’s internal machinery leads to the aberrant “sugar coating” of proteins, a hallmark of cancer progression.

The research, led by Professor Kevin J. Naidoo, working with Dr. Lateef Nashed (SCRU Glycobiomedical laboratory) and SCRU computational scientists Dr. Tharindu Senapthi and doctoral student Kyllen Dilsook, focused on Mucin 1 (MUC1), a protein that behaves very differently in healthy and cancerous cells due to changes in glycosylation, the process by which sugar molecules attach to proteins. Using a novel “one-pot” synthetic biology method, combined with advanced computer-based reaction simulations, the team recreated the complex conditions found inside the cell’s Endoplasmic Reticulum (ER) and Golgi apparatus.

A key discovery of the study is that in cancer cells, initiation enzymes known as GALNTs relocate from the Golgi to the ER. This spatial shift extends reaction times and prevents inhibition by other enzymes, resulting in complete “Tn antigen” occupancy of the MUC1 protein. Furthermore, the study identified that the enzyme ST6GALNAC1 has a strict preference for a specific location on the protein, the T13 site, which drives the high-density synthesis of the tumor-associated sialyl-Tn (sTn) antigen.

“Our systems modeling approach allows us to decode the enzyme localization and substrate specificities that are fundamental to tumorigenesis,” said principal investigator Professor Naidoo. “By understanding exactly how these cancer-associated antigens are built, we open new doors for the development of precision vaccines and targeted drug discovery.”

The study, titled “An in vitro approach for simulating divergent Golgi O-glycosylation of tumor-associated MUC1 from normal MUC1,” represents a significant leap in glycobiology, moving beyond simple gene expression to a mechanistic understanding of how metabolic networks are rewired in disease.

By developing a “one-pot” synthetic biology assembly line and using advanced computer simulations, the research team has decoded how the relocation of glycoenzymes in cancer cells leads to the high-density synthesis of tumor-associated antigens. Specifically, the team has identified the T13 site as the primary target for sialylation. This is a finding with significant implications for cancer vaccine and drug development.

The content on this page is provided for information only